Latest Immunogen (IMGN) Headlines IDEXX Laborat
Post# of 97
Posted On: 03/12/2014 10:26:21 PM
Latest Immunogen (IMGN) Headlines
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Thu Feb 27, 3:39PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
ImmunoGen, Inc. (IMGN) Catches Eye: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:44AM CST
ImmunoGen, Inc. was a big mover last session, as the company saw its shares rise a little over 6% on the day.
ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer
Business Wire - Thu Feb 20, 5:30AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty years of senior level Human Resources (HR) experience. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
ImmunoGen's Q2FY14 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 8:50AM CST
ImmunoGen's second quarter fiscal 2014 earnings of 4 cents per share, compared favourably to the Zacks Consensus Estimate of a loss of 19 cents.
Milestone Payments Push ImmunoGen to a Q2 Profit
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 11:10AM CST
Antibody-drug conjugate developer ImmunoGen reported its second-quarter earnings results before the opening bell today, and early indications continue to point toward ADC technology being the next wave of cancer treatments based on these...
Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea
George Budwell, The Motley Fool - Motley Fool - Fri Jan 31, 8:17AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a look at...
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
Business Wire - Fri Jan 31, 5:35AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric Guempel as Vice President of Product Strategy and Program Management. Mr. Guempel brings to ImmunoGen more than 30 years of experience in the healthcare industry, including extensive experience in commercial functions related to the strategic development of novel oncology products. He reports to Dr. Charles Morris, Executive Vice President and Chief Development Officer of ImmunoGen.
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update
Business Wire - Fri Jan 31, 5:30AM CST
--Progress with all three wholly owned ImmunoGen compounds in clinical testing - IMGN853, IMGN529, IMGN289; decision made to discontinue IMGN901 development.
GlaxoSmithKline and Personalized Medicine Take Another Leap Forward
Cory Renauer, The Motley Fool - Motley Fool - Sun Jan 26, 9:30AM CST
Earlier this month, the FDA granted an accelerated approval to GlaxoSmithKline for Mekinist and Tafinlar as an oral combination therapy for treatment of patients with inoperable melanoma. Merck has a promising new compound that may give it some...
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results
Business Wire - Fri Jan 24, 5:30AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 31, 2014, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2013. Management also will provide an update on the Company.
Space Ape Games Turns to Swrve's Relationship Marketing Platform to Optimize First-time User Experience and Boost Retention
PR Newswire - Wed Jan 22, 8:00AM CST
Swrve, the leader in relationship marketing for mobile apps, today announced it is working with mobile game pioneer Space Ape Games to help improve player retention, loyalty and in-game revenue.
Upcoming Earnings Schedule, Supply and Collaboration Agreements, Financial Results, and Stock Options - Research Report on Natus, Haemonetics, AngioDynamics, Horizon Pharma, and ImmunoGen
PR Newswire - Wed Jan 15, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Natus Medical, Inc. (NASDAQ: BABY), Haemonetics Corporation (NYSE: HAE), AngioDynamics, Inc. (NASDAQ: ANGO), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
JPMorgan Healthcare Conference Highlights: ImmunoGen
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 14, 10:05AM CST
Yesterday kicked off the start of the 2014 JPMorgan Healthcare Conference, which is arguably the most important health-care conference of the year, bringing together pharmaceutical, biotechnology, and medical device makers all under one roof. Just...
Critical Alerts For AT&T, Gold SPDR, Arrowhead Research, Johnson & Johnson, and ImmunoGen Released By InvestorsObserver
PR Newswire - Tue Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for T, GLD, ARWR, JNJ, and IMGN.
AbbVie Inc. Invests in Precision-Bombing Cancer Therapies
Cory Renauer, The Motley Fool - Motley Fool - Mon Jan 13, 5:30PM CST
Humira is really raking it in for AbbVie , but the good times will likely take a turn for the worse when the biologic goes off patent in a few years. For reasons I explained recently, Humira sales are more likely to slide down a bunny slope than...
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
Business Wire - Thu Jan 09, 5:29AM CST
CytomX Therapeutics, the Probody(TM) therapeutics company, and ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its validated, industry-leading antibody-drug conjugate (ADC) technology, today announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. Probodies are a potentially disruptive class of antibody therapeutics that may further broaden the opportunities for ADCs by localizing therapeutic activity to the tumor microenvironment.
"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 07, 12:25PM CST
We may not be able to beam people from point A to B just yet as they did in Star Trek , but the pace of innovation within the biopharmaceutical sector is breathtaking at times. The evolution of hepatitis-C therapies over the past two-and-a-half...
Conference Presentation Schedules, Executive Appointments, and Product Availability - Research Report on Mallinckrodt, Haemonetics, Select Medical, Horizon Pharma, and ImmunoGen
PR Newswire - Tue Jan 07, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Mallinckrodt plc (NYSE: MNK), Haemonetics Corporation (NYSE: HAE), Select Medical Holdings Corporation (NYSE: SEM), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Thu Feb 27, 3:39PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
ImmunoGen, Inc. (IMGN) Catches Eye: Stock Jumps 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:44AM CST
ImmunoGen, Inc. was a big mover last session, as the company saw its shares rise a little over 6% on the day.
ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer
Business Wire - Thu Feb 20, 5:30AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty years of senior level Human Resources (HR) experience. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
ImmunoGen's Q2FY14 Earnings Surpass Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 8:50AM CST
ImmunoGen's second quarter fiscal 2014 earnings of 4 cents per share, compared favourably to the Zacks Consensus Estimate of a loss of 19 cents.
Milestone Payments Push ImmunoGen to a Q2 Profit
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 31, 11:10AM CST
Antibody-drug conjugate developer ImmunoGen reported its second-quarter earnings results before the opening bell today, and early indications continue to point toward ADC technology being the next wave of cancer treatments based on these...
Enanta Pharmaceuticals, Inc., ImmunoGen, Inc. and Prana Biotechnology Ltd Could Be Big Movers in Hea
George Budwell, The Motley Fool - Motley Fool - Fri Jan 31, 8:17AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a look at...
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
Business Wire - Fri Jan 31, 5:35AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric Guempel as Vice President of Product Strategy and Program Management. Mr. Guempel brings to ImmunoGen more than 30 years of experience in the healthcare industry, including extensive experience in commercial functions related to the strategic development of novel oncology products. He reports to Dr. Charles Morris, Executive Vice President and Chief Development Officer of ImmunoGen.
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update
Business Wire - Fri Jan 31, 5:30AM CST
--Progress with all three wholly owned ImmunoGen compounds in clinical testing - IMGN853, IMGN529, IMGN289; decision made to discontinue IMGN901 development.
GlaxoSmithKline and Personalized Medicine Take Another Leap Forward
Cory Renauer, The Motley Fool - Motley Fool - Sun Jan 26, 9:30AM CST
Earlier this month, the FDA granted an accelerated approval to GlaxoSmithKline for Mekinist and Tafinlar as an oral combination therapy for treatment of patients with inoperable melanoma. Merck has a promising new compound that may give it some...
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results
Business Wire - Fri Jan 24, 5:30AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 31, 2014, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2013. Management also will provide an update on the Company.
Space Ape Games Turns to Swrve's Relationship Marketing Platform to Optimize First-time User Experience and Boost Retention
PR Newswire - Wed Jan 22, 8:00AM CST
Swrve, the leader in relationship marketing for mobile apps, today announced it is working with mobile game pioneer Space Ape Games to help improve player retention, loyalty and in-game revenue.
Upcoming Earnings Schedule, Supply and Collaboration Agreements, Financial Results, and Stock Options - Research Report on Natus, Haemonetics, AngioDynamics, Horizon Pharma, and ImmunoGen
PR Newswire - Wed Jan 15, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Natus Medical, Inc. (NASDAQ: BABY), Haemonetics Corporation (NYSE: HAE), AngioDynamics, Inc. (NASDAQ: ANGO), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
JPMorgan Healthcare Conference Highlights: ImmunoGen
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 14, 10:05AM CST
Yesterday kicked off the start of the 2014 JPMorgan Healthcare Conference, which is arguably the most important health-care conference of the year, bringing together pharmaceutical, biotechnology, and medical device makers all under one roof. Just...
Critical Alerts For AT&T, Gold SPDR, Arrowhead Research, Johnson & Johnson, and ImmunoGen Released By InvestorsObserver
PR Newswire - Tue Jan 14, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for T, GLD, ARWR, JNJ, and IMGN.
AbbVie Inc. Invests in Precision-Bombing Cancer Therapies
Cory Renauer, The Motley Fool - Motley Fool - Mon Jan 13, 5:30PM CST
Humira is really raking it in for AbbVie , but the good times will likely take a turn for the worse when the biologic goes off patent in a few years. For reasons I explained recently, Humira sales are more likely to slide down a bunny slope than...
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
Business Wire - Thu Jan 09, 5:29AM CST
CytomX Therapeutics, the Probody(TM) therapeutics company, and ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its validated, industry-leading antibody-drug conjugate (ADC) technology, today announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. Probodies are a potentially disruptive class of antibody therapeutics that may further broaden the opportunities for ADCs by localizing therapeutic activity to the tumor microenvironment.
"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 07, 12:25PM CST
We may not be able to beam people from point A to B just yet as they did in Star Trek , but the pace of innovation within the biopharmaceutical sector is breathtaking at times. The evolution of hepatitis-C therapies over the past two-and-a-half...
Conference Presentation Schedules, Executive Appointments, and Product Availability - Research Report on Mallinckrodt, Haemonetics, Select Medical, Horizon Pharma, and ImmunoGen
PR Newswire - Tue Jan 07, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Mallinckrodt plc (NYSE: MNK), Haemonetics Corporation (NYSE: HAE), Select Medical Holdings Corporation (NYSE: SEM), Horizon Pharma, Inc. (NASDAQ: HZNP), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
(0)
(0)ImmunoGen Inc. (IMGN) Stock Research Links
Scroll down for more posts ▼